This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

June 9, 2026
5 min

The Medicine Maker

At a Glance

Category	Detail
Condition	Advanced squamous non-small cell lung cancer
Key Mechanisms	PD-1/VEGF bispecific antibody
Target Population	Patients with advanced squamous NSCLC
Care Setting	Oncology

Key Highlights

median_survival_rates
adverse_events

Guideline-Based Recommendations

Diagnosis

Management

Ivonescimab plus chemotherapy as first-line treatment for advanced squamous NSCLC based on HARMONi-6 trial results.

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Adults with advanced squamous NSCLC.

Ivonescimab shows significant survival benefits compared to standard therapies.

Clinical Best Practices

Consider ivonescimab for patients not responding to standard PD-1 therapies.
Regularly assess patient response and adverse events during treatment, including specific monitoring for grade 3 or higher events.